When a superior molecule is held back by its delivery system
Naproxen’s long-lasting effect is well known. Its slow start is the more interesting story — and the clearest example of how formulation, not chemistry, now decides whether a good drug performs.
By Ibumix · 7-minute read
__________________________________________________________________
The paradox of naproxen
Naproxen is, by most measures, one of the better non-steroidal anti-inflammatory drugs. Its half-life of roughly twelve to seventeen hours is among the longest of the common NSAIDs, giving sustained anti-inflammatory cover from once- or twice-daily dosing. And in the largest randomised safety trial of its kind — PRECISION, which followed 24,081 arthritis patients at elevated cardiovascular risk for a mean of almost three years — naproxen stood level with celecoxib and ibuprofen on the primary cardiovascular endpoint, and is widely regarded as carrying the most favourable cardiovascular profile of the non-selective NSAIDs.
And yet, to the people who take it, naproxen often feels slower and less responsive than ibuprofen. A superior molecule, by reputation, that underwhelms in the moment.
The reason is not the molecule. It is the tablet.
Half-life is not onset
Half-life decides how long a drug lasts. Absorption decides whether anyone notices it has started.
Naproxen’s defining feature — its long half-life — describes how slowly the drug leaves the body. It says nothing about how quickly the drug arrives. Onset is governed by absorption, and absorption begins with dissolution. This is where naproxen runs into trouble.
The absorption bottleneck
Naproxen is a BCS Class II drug: highly permeable, but poorly soluble. Its rate of absorption is limited not by the gut’s ability to take it up, but by how slowly it dissolves in the first place. In a conventional tablet, that single property shapes the entire experience.
The numbers make the point. Immediate-release naproxen tablets reach peak plasma concentration at around 2.3 hours. The more soluble sodium salt is absorbed faster — the approved labelling notes the onset of pain relief beginning within roughly 30 minutes for naproxen sodium, against about an hour for naproxen acid. Same molecule; a different salt, a different dissolution behaviour, and a materially different time to relief.
The pattern is consistent: wherever naproxen is made easier to dissolve, it acts faster; where it is left to dissolve slowly, the patient waits — and the wait is variable, dependent on stomach contents, gastric pH and motility on the day.
The molecule is strong. The delivery is weak.
Why liquid naproxen is rare — and not by accident
If a more soluble, pre-dissolved naproxen acts faster, the obvious question is why adult liquid naproxen is so uncommon. The answer is that it is genuinely hard to make.
- Solubility. Naproxen resists staying dissolved at the concentrations an adult dose requires; simple solutions risk settling and inconsistency.
- Dose size. Adult naproxen doses are relatively high, demanding larger volumes and careful suspension design.
- Taste. Naproxen is bitter and difficult to mask — a particular problem for any oral liquid or spray.
None of these is trivial. Together they have been enough to keep the category effectively empty — and to keep a good molecule in a format that holds it back.
The conservative formulation trap
There is a second reason, and it is commercial rather than chemical. Naproxen sits in a risk-averse zone: widely used, clinically trusted, off-patent and commercially stable. Reformulating it introduces regulatory work, cost and perceived risk to a product that already sells. The rational institutional response is to leave it alone — don’t change what isn’t broken, even when “not broken” quietly means “not optimal.”
The cost of that inertia is easy to underestimate. More than 500 million people live with osteoarthritis worldwide, a figure projected to approach one billion by mid-century, and NSAIDs remain among the most consumed medicines on earth. Guidelines have already moved: the UK’s NICE now recommends topical NSAIDs as a first-line option for knee and hand osteoarthritis, ahead of oral NSAIDs, precisely because how a drug is delivered changes its risk–benefit balance. The format is no longer a detail. It is the decision.
What a re-engineered naproxen looks like
Fast onset and long duration are not in tension. The tablet simply could never deliver both at once.
Naproxen’s problem is bounded and specific: the start. Everything downstream — duration, steady plasma levels, cardiovascular profile — is already a strength. Fix the onset without disturbing the rest, and the same molecule behaves like a better one.
That is a formulation problem, and it has a formulation answer. Presenting naproxen to the gut already dissolved — in a solubilised liquid, or a single metered oral spray — removes the dissolution step the tablet makes you wait through. The dose no longer queues behind the slowest part of the process. The result is the combination conventional tablets struggle to reach: fast onset, with naproxen’s natural long duration left intact.
The architecture that makes this possible is a lipid one. Ibumix builds its liquid systems on glyceryl caprate (GCC), a medium-chain lipid that does three jobs at once: it solubilises the active, it self-assembles into a structured liquid-crystal matrix, and it holds everything evenly in suspension. That suspending power has a further consequence a tablet can never match — the formulation can carry additional food-grade ingredients alongside the active, from honey to omega-3 to olive oil, integrated into the same structured phase rather than fighting it.
A tablet is finished. A liquid can be built on.
There is also a quieter benefit. A liquid or spray asks nothing of the patient’s ability to swallow a tablet — a daily obstacle for older adults and anyone with dysphagia, who are disproportionately the people taking an NSAID every day.
One thing this is not is a patch. Naproxen’s dose is simply too large to drive through skin across a sensible area — which is exactly why no naproxen patch exists in any market. The right format for this molecule is a liquid that can carry the dose with ease. The molecule chooses the format; the format is not imposed on it.
The industry blind spot
Naproxen exposes a pattern that reaches well beyond one drug. Pharma has spent decades optimising for stability, manufacturability and familiarity — the priorities of the production line — rather than for performance in the patient. A molecule with excellent intrinsic properties can be locked into a suboptimal format for no better reason than that the format already exists and the molecule already sells.
Chemistry is expensive and slow to change. Formulation is where meaningful innovation is now both possible and affordable. The distinction matters, because it tells you where the next decade of improvement will actually come from.
The Ibumix perspective
Naproxen is not a limitation of chemistry. It is a limitation of formulation — and that is a far more hopeful diagnosis, because formulation is the part that can be fixed.
Ibumix is developing Naproxymix, the second active chassis on its lipid-formulation platform, as exactly this: sodium naproxen, re-presented as a liquid and an oral spray engineered to decouple onset from dissolution while preserving the duration that makes naproxen worth taking. The architecture and the development target are on record; the proof-of-concept data is still to be generated, and will be reported as it is produced.
Naproxen has worked, more or less, for half a century. The point of this case study is simpler than a critique: it works, but it could work far better — and the gap between those two statements is where the future of pharma now lives.
______________________________________________________________________________
About Ibumix
Ibumix is developing a series of new liquid drug delivery platforms built on glyceryl caprate (GCC) lipid chemistry — re-engineering how established medicines are delivered, beginning with the NSAID class. Ibuprofen and naproxen are the starting points; the opportunity extends well beyond them.
Sources
- Naproxen pharmacokinetics, Tmax and onset (tablet, suspension and sodium salt) — FDA NAPROSYN / naproxen prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017581s111,018164s061,018965s020,020067s018lbl.pdf
- Clinical pharmacokinetics of naproxen (half-life ~12–17 h) — Davies NM, Anderson KE. Clin Pharmacokinet. 1997;32(4):268–293
- Cardiovascular safety of naproxen vs celecoxib and ibuprofen (PRECISION, n=24,081) — Nissen SE et al. N Engl J Med. 2016;375(26):2519–2529 https://www.nejm.org/doi/full/10.1056/NEJMoa1611593
- Topical NSAIDs recommended first-line for knee and hand osteoarthritis — NICE guideline NG226, Osteoarthritis in over 16s (2022) https://www.nice.org.uk/guidance/ng226
- Global osteoarthritis prevalence (>500 million; rising) — World Health Organization, Osteoarthritis fact sheet https://www.who.int/news-room/fact-sheets/detail/osteoarthritis
- BCS Class II classification of naproxen (poorly soluble, highly permeable) — Biopharmaceutics Classification System literature